A phase 2, randomized, placebo-controlled, double-blind multiple ascending dose study in patients with cystic fibrosis carrying the 3849 +10 kb C->t mutation to evaluate the safety, tolerability, phamacokinetics and preliminary efficacy of SLP84

• Protocol code: SPL84-002
• EudraCT code: No aplica
• Research group: Pneumology
• Service: Pneumology
• Principal investigator:  Álvarez Fernandez, Antonio
• Pathology: Malalties del sistema respiratori
• Phase: Fase II
• Status: Recruiting volunteers

Estudio fase IIb, aleatorizado, doble ciego, controlado con placeboy con comparador activo abierto para evaluar la eficacia, seguridad y tolerabilidad deAZD5004 en adultos con diabetes mellitus tipo 2

• Protocol code: D7261C00001
• EudraCT code: No aplica
• Research group: Diabetes and Metabolism
• Service: Endocrinology
• Principal investigator:  Ciudin Mihai, Andreea
• Pathology: Malalties endocrines, nutricionals i metabòliques
• Phase: Fase II

“Efficacy and safety of co administered cagrilintide and semaglutide(CagriSema) once weekly versus placebo in participants with type 2diabetes and painful diabetic peripheral neuropathy

• Protocol code: NN9388-7864
• EudraCT code: No aplica
• Research group: Diabetes and Metabolism
• Service: Endocrinology
• Principal investigator:  Ortiz Zuñiga, Angel Michael
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase II
• Status: Recruiting volunteers

Estudio de fase 3, aleatorizado, doble ciego y controlado con tratamiento activo para evaluar el cambio a una pauta semanal de islatravir/lenacapavir por vía oral en personas con VIH-1 con supresión virológica bajo tratamiento con bictegravir/emtricitabina/tenofovir (B/F/TAF)

• Protocol code: GS-US-563-5925
• EudraCT code: No aplica
• Research group: Infectious Diseases
• Service: Infectious
• Principal investigator:  Curran Fàbregas, Adria
• Pathology: Certes malalties infeccioses i parasitàries
• Phase: Fase III
• Status: Recruiting volunteers

' Efficacy and safety of co-administered cagrilintide and semaglutide(CagriSema 2.4 mg/2.4 mg) once-weekly versus semaglutide 2.4 mg,cagrilintide 2.4 mg and placebo in people with chronic kidneydisease and type 2 diabetes living with overweight or obesity.'

• Protocol code: NN9388-7700
• EudraCT code: No aplica
• Research group: Nephrology and kidney transplantation
• Service: Nephrology
• Principal investigator:  Soler Romeo, Maria Jose
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase II